Salute e Benessere

Roche announces new results from EMBARK demonstrating significant sustained…

Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR) and 10-meter walk/run (10MWR), results were statistically significant and clinically meaningful two years after treatment with Elevidys, compared to a pre-specified propensity-weighted untreated external control groupFunctional differences between individuals treated with Elevidys and those in the external control group increased between one year and two years after treatmentNo new...
Nasdaq GlobeNewswire
27/01/2025

Arab Health 2025｜Yuwell Medical Announces Strategic Investment and Partnership…

He further emphasized, "In the process of realizing the new vision, Yuwell will work hand in hand with global partners to provide users with more competitive products and better health solutions." He further emphasized, "In the process of realizing the new vision, Yuwell will work hand in hand with global partners to provide users with more competitive products and better health solutions." During the conference, Yuwell Medical and the American company Inogen formalized their…
PR Newswire
27/01/2025

FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the…

Alzheimer's disease is caused by a continuous underlying neurotoxic process that begins before and continues after plaque removal. Continuous administration of Leqembi is of great value to patients as Leqembi works to fight Alzheimer's Disease in two ways: not only rapidly clearing the amyloid-beta (Aβ) plaque, but it also works to fight the progressive nature of Alzheimer's disease by continuously clearing the highly toxic protofibrils that otherwise continue to cause neuronal injury. ...
PR Newswire
27/01/2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment…

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapyTOKYO and CAMBRIDGE, Mass., Jan.26, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:...
Nasdaq GlobeNewswire
27/01/2025

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 24, 2025 –Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity...
Nasdaq GlobeNewswire
24/01/2025

Silver Gene to Present at DxPx Conference Europe 2025: Showcasing Genetic…

Silver Gene's presentation will highlight the company's cutting-edge methodology, which combines advanced nutritional genetic technology with the expertise of a nationwide network of physicians. By analyzing multifactorial genes and identifying underlying genetic causes, Silver Gene provides comprehensive evaluations designed to eliminate toxins, restore health, and deliver lasting solutions for patients who have struggled to find answers elsewhere. Silver Gene's presentation will highlight…
PR Newswire
24/01/2025

Press release: Sequana Medical Announces New Share Capital Amount and New Number…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES FOLLOWING LOAN CONVERSIONS Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under the 2024 convertible loan with various shareholders, and EUR 2.68 million under the Kreos 2022 loan into equity, reduces net debt by EUR 4.50 million Ghent, Belgium, 24 January 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the...
Nasdaq GlobeNewswire
24/01/2025

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization…

About X4 Pharmaceuticals About X4 Pharmaceuticals X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of...
PR Newswire
24/01/2025

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to…

PRESS RELEASEAB SCIENCE WILL HOST A LIVE WEBCAST ON TUESDAY JANUARY 28, 2025 FROM 5.30PM TO 6.45PM CETParis, 24 January 2025, 6pm CETAB Science SA(Euronext – FR0010557264 – AB) will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET. The agenda of this live webcast will be to provide an update on masitinib platform.The following attendees will participate to the live webcast: Alain Moussy, co-founder and CEO of AB ScienceOlivier Hermine, MD, PhD,...
Nasdaq GlobeNewswire
24/01/2025

Luxury Goods Market Insights: Key Segments, Emerging Trends, and Forecast to…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-0R6457/Global_Luxury_Goods_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-0R6457/Global_Luxury_Goods_Market Major Factors Driving the Growth of Luxury Goods Market: The market is characterized by the presence of renowned luxury brands that leverage heritage, craftsmanship, and exclusivity to attract affluent consumers. Continuous innovation in product design,...
PR Newswire
24/01/2025

US Healthcare Environmental Services Market to Hit USD 9,529.4 Million by 2029…

New healthcare facilities are being established due to a rise in surgical procedures, necessitating extensive environmental services to uphold stringent safety & cleanliness regulations. Regulatory bodies such as the Centers for Disease Control (CDC) and OSHA's regulatory guidelines are also expected to create growth opportunities for market players. Key healthcare facilities outsource their environmental services to specialized vendors who enable them to meet stringent criteria…
PR Newswire
24/01/2025

Anti-snoring Devices Market to Hit USD 1.45 Billion by 2029 with 9.8% CAGR |…

The fastest-growing device segment is the oral appliances segment, which includes mandibular advancement devices (MADs) and tongue-retaining/stabilizing devices (TRDs). The large share of the oral appliances segment can be attributed to the growing awareness among healthcare providers & patients regarding the cost-efficiency and easy availability of oral appliances. Additionally, government initiatives promoting awareness about snoring and untreated sleep apnea are expected to improve…
PR Newswire
24/01/2025

/C O R R E C T I O N -- PAGE Therapeutics AG/

The presence of CTC clusters in patients' blood is associated with poor prognosis, and preclinical studies conducted by Prof Aceto and other groups have shown how CTCs have much higher potential to seed metastases when travelling as clusters rather than when traveling as single cells. Furthermore, in preclinical cancer models, treatment with Na+/K+ ATPase inhibitors enables the reduction of CTC clusters and metastases, opening up a new potential cancer treatment paradigm based on which…
PR Newswire
24/01/2025

Clinical trial published in Nature Medicine shows proof of concept of PAGE's…

The present clinical study, published in the top-tier scientific journal Nature Medicine (link), has shown for the first time that the same effect on clusters can be achieved in humans. A cohort of 9 metastatic breast cancer patients were treated with digoxin for one week and evaluated against a control group. The primary endpoint – a reduction in size of CTC clusters – was met, with a statistically significant average reduction of 2.2 cells per cluster. The present clinical study, published…
PR Newswire
24/01/2025

SoftSmile and ClearCorrect Announce Settlement

About SoftSmileSoftSmile is a New York-based technology company that helps orthodontists to deliver custom, high-quality, and affordable treatment to their patients. Established in 2020, SoftSmile designs and develops an advanced, AI-driven orthodontic software that applies innovative approaches in a user-friendly interface. This product gives orthodontists unparalleled control and precision of the treatment they deliver to their patients. SoftSmile was created by doctors, for doctors...
Nasdaq GlobeNewswire
24/01/2025

Winter Davos 2025: Yidu Tech Accelerates Global Expansion of AI-Powered…

Ms. Gong highlighted Yidu Tech's impact, including 240+ scientific publications, a 40% improvement in clinical trial efficiency, and health insurance solutions benefiting 34 million policyholders. She emphasized the role of digital health in enabling personalized care and smarter decision-making. Ms. Gong highlighted Yidu Tech's impact, including 240+ scientific publications, a 40% improvement in clinical trial efficiency, and health insurance solutions benefiting 34 million…
PR Newswire
24/01/2025

Biomimetic Innovations Ltd, an affiliate of PBC Biomed, Announces an Exclusive…

Sanara is a medical technology company based in Fort Worth, Texas, focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare market.Sanara has acquired the exclusive U.S. marketing, sales, and distribution rights to OsStic ®Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (“OsStic ® ”) under the terms of the License and Distribution Agreement, as well as a...
Nasdaq GlobeNewswire
24/01/2025

Director/PDMR Shareholding

DXS INTERNATIONAL PLC(AQSE: DXSP)Notification of Director / PDMR DealingDXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 23 January, Mr Bob Sutcliffe, the Chairman, purchased 50,000 Ordinary Shares in the Company at a price of 2.0p per share, and on 24 January, Mr Sutcliffe, purchased a further...
Nasdaq GlobeNewswire
24/01/2025

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous…

Bagsværd, Denmark, 24 January 2025– Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending...
Nasdaq GlobeNewswire
24/01/2025

BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

In order to provide sufficient time for additional investors to participate in the Private Placement, the Company has extended the closing date of its fourth and final tranche (the "Final Tranche") of the Private Placement previously scheduled for January 24, 2025, to on or about, but no later than, February 7, 2025. The Company intends to use the net proceeds of the Final Tranche for working capital. All securities to be issued pursuant to the Final Tranche will be subject to a…
PR Newswire
24/01/2025

70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical…

Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report Request a sample and discover the recent advances in dry AMD treatment drugs @ Dry Age-Related Macular Degeneration Pipeline Report The dry AMD pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage dry AMD drugs, inactive and dormant assets, a comprehensive assessment...
PR Newswire
23/01/2025

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 23, 2025 –Genmab A/S(Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date...
Nasdaq GlobeNewswire
23/01/2025

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury…

Spinal cord injury is a devastating global health issue with profound implications for both mortality and morbidity. The inflammatory response mediated by microglia is a critical component in the pathogenesis of SCI. In these studies, the preclinical model was subjected to a spinal cord injury and then was treated with nasal anti-CD3, resulting in notable advancements in motor functions.Furthermore, spinal cord injuries (SCIs) are complex neurotraumatic wounds affecting military Service...
Nasdaq GlobeNewswire
23/01/2025

Nevisense (EIS) included in updated German (S1) imaging guidelines

"The guidelines have a primary focus on imaging technologies, so it is very positive that they include Nevisense and state that it is a valuable technology in detecting skin cancer. The guideline includes the potential future of new applications within AD. This is another step forward in the adoption of our technology in Germany", said Pia Renaudin, CEO of SciBase. "The guidelines have a primary focus on imaging technologies, so it is very positive that they include Nevisense and…
PR Newswire
23/01/2025
Altri  Comunicati